3D InSight™ Human Liver Microtissues

This resource describes the handling, maintenance, and transfer of 3D InSight™ microtissues in Akura™ 96 Spheroid Microplates. It outlines essential steps including handling upon arrival, medium exchange, and microscopic analysis to ensure reproducible and reliable in vitro results.

The protocol highlights best practices for preserving microtissue integrity, including controlled pipetting techniques and semi-automated workflows. These approaches support consistent long-term culture and downstream applications such as drug testing, imaging, and biochemical assays.

Resource details:

• Resource type: Application note
• Page count: 18
• Read time: 27 mins

Explore 3D InSight™ species-specific liver microtissues – assay-ready 3D in vitro liver models designed to provide physiologically relevant and reproducible results for laboratory studies. The microtissues consist of co-cultured primary hepatocytes and non-parenchymal cells, enabling more accurate simulation of liver function compared to traditional 2D cultures.

Delivered in a standardized microplate format, the system supports high-throughput and automation-ready workflows, with applications including drug safety, hepatotoxicity assessment, and disease modeling. Discover how the models maintain metabolic activity and functionality for extended culture periods, supporting long-term studies and consistent experimental outcomes.

Resource details:

• Resource type: Application note
• Page count: 21
• Read time: 34 mins

This poster highlights assay-ready 3D InSight™ Human Liver Microtissues, physiologically relevant 3D spheroid models designed to accelerate drug discovery and translational research workflows. The models combine primary hepatocytes with non-parenchymal cells to deliver reproducible, human-relevant data across a range of applications.

Delivered in a standardized microplate format, the system supports high-throughput and long-term studies with sustained metabolic activity for up to 28 days. Discover how by eliminating the need for in-house model development, the platform enables faster experimental setup and more consistent results in preclinical safety, efficacy, and pharmacokinetic studies.

Resource details:

• Resource type: Scientific poster
• Page count: 2
• Read time: 3 mins

This flyer highlights the applications of 3D InSight™ Liver Microtissues, assay-ready 3D liver spheroid models designed for drug discovery and translational research. Discover how the platform enables researchers to generate human-relevant data across a wide range of applications, including safety testing, pharmacokinetics, and disease modelling.

The Microtissues support advanced workflows such as drug-induced liver injury (DILI) prediction, mechanistic toxicology, antiviral research, and multi-organ studies. By providing standardized, ready-to-use models, the system helps streamline experimental workflows and improve reproducibility in preclinical research.

Resource details:

• Resource type: Scientific poster
• Page count: 2
• Read time: 3 mins

This product manual outlines 3D InSight™ Human Liver Microtissues from InSphero, assay-ready 3D spheroid models designed to deliver reproducible and physiologically relevant data for in vitro studies. The Microtissues combine primary human hepatocytes with non-parenchymal liver cells, supporting more accurate modelling of liver function compared with traditional 2D systems.

Delivered pre-aggregated in microplate format, the platform supports high-throughput and long-term studies, maintaining metabolic activity and functionality for up to four weeks. The models are used across applications including drug safety testing, metabolism studies, and translational research, enabling more reliable and scalable workflows.

Resource details:

• Resource type: Application notes
• Page count: 28
• Read time: 42 mins

This whitepaper explores the use of cross-species 3D liver microtissues to improve prediction of drug-induced liver injury (DILI) during preclinical development. Using a case study, the work demonstrates how advanced in vitro models can reveal species-specific mechanisms of toxicity that are not captured using traditional animal models or short-term cytotoxicity assays.

By combining long-term exposure studies with functional and transcriptomic analysis, the models enable identification of complex toxicity pathways and support more accurate human risk assessment. The findings highlight the value of integrating 3D in vitro liver systems early in drug discovery workflows to reduce late-stage attrition and improve translational outcomes.

Resource details:

• Resource type: Whitepaper
• Page count: 12
• Read time: 20 mins

Insphero offers advanced 3D in vitro technology for immuno-oncology screening, and presents the 3D InSight™ Tumor Microtissue in the assessment of Antibody-Drug Conjugates (ADCs) efficacy and penetration depth. InSphero further highlights the product's capabilities including the evaluation of various therapeutic modalities, such as antibody-based therapeutics, with confidence, covering mechanisms of action, immune cell engagement, off-target effects, and more.

Tumor spheroids are three-dimensional cellular models that mimic the complex microenvironment of tumors, facilitating advanced drug screening and research in oncology. InSphero introduces 3D InSight™ Tumor Spheroids for advanced immuno-oncology (IO) drug discovery. The spheroids offer high physiological relevance, scalability, and reliability, effectively modeling the complex tumor microenvironment (TME). With a wide array of tumor cell lines, including cancer-associated fibroblasts (CAFs) and immune cells, these spheroids mimic tumor heterogeneity and microenvironment interactions.

3D tumor spheroids comprise of various tumor cell lines and components of the tumor microenvironment, therefore accurate testing of anti-cancer therapies while maintaining consistency and reproducibility can prove challenging. InSphero highlights human 3D InSight™ Tumor Spheroids, offering a blend of physiological relevance, scalability, and reliability for oncology therapeutic testing. With the flexibility to accommodate different throughput needs and the capability to mimic tumor heterogeneity, they provide a robust platform for advanced drug discovery in oncology.

Cancer ranks as the second leading cause of death globally, with immunotherapy offering promise but facing limitations in clinical success. Recent studies reveal that overexpression of PU.1, IRF8, and BATF3 transcription factors induces the transformation of tumor cells into antigen-presenting dendritic cells, potentially enhancing anticancer immunity. However, existing testing platforms struggle to replicate the intricate cell interactions necessary to validate this approach. InSphero presents the 3D InSight™ Oncology Platform as a tool to assess the efficacy and immune-stimulatory effects of tumor-dendritic cell reprogramming.

InSphero’s 3D InSight™ Microtissues are assay-ready 3D spheroid models designed to accelerate drug discovery workflows. In this video, discover how these physiologically relevant microtissues integrate directly into laboratory processes, enabling researchers to generate consistent and human-relevant data from early-stage studies.

3D InSight Human Liver Disease platform provides the most physiologically relevant testing environment for efficacy and safety